文献速递肝病

索磷布韦联合维帕他韦改善丙型肝炎病毒感染患者报告结局,无论是否伴代偿或失代偿期肝硬化

Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2016-11-12

该研究对4项3期临床试验中1701例不同基因型HCV感染患者进行事后分析,比较含或不含利巴韦林的索磷布韦联合维帕他韦方案对患者报告结局的影响。结果显示,无利巴韦林方案在治疗第4周起即提高代偿及失代偿期肝硬化患者的PRO评分,且无统计学显著下降;含利巴韦林方案虽出现PRO一过性下降,但停药后12周内均恢复。

要点

  • 失代偿期肝硬化患者基线PRO评分较无肝硬化者最多低33.5%(P < .05)。
  • 含利巴韦林方案治疗期间PRO评分可较基线升高最多11.8%或降低最多7.1%(P < .05),停药后12周内下降均恢复。
  • 无利巴韦林的索磷布韦联合维帕他韦方案从治疗第4周起提高PRO评分,代偿期肝硬化改善,失代偿期改善更明显,各时间点无统计学显著下降(所有单侧P值 > .05)。

核心结论

  • 在4项3期临床试验数据的事后分析中,HCV感染患者(尤其是失代偿期肝硬化患者)在接受索磷布韦联合维帕他韦治疗期间及获得持续病毒学应答后,PRO评分显著升高。

研究设计与样本

  • 对ASTRAL-1、-2、-3和-4四项3期临床试验中1701例不同基因型HCV感染患者进行事后分析。
  • 患者接受含利巴韦林的索磷布韦联合维帕他韦12周(n = 87)、索磷布韦联合利巴韦林12或24周(n = 401)、无利巴韦林的索磷布韦联合维帕他韦12或24周(n = 1213)。
  • 所有试验中,参与者在多个时间点完成4份PRO问卷(对HCV RNA水平设盲):Short Form-36、Functional Assessment of Chronic Illness Therapy-Fatigue、Chronic Liver Disease Questionnaire-HCV Version和Work Productivity and Activity Impairment: Specific Health Problem。
  • 比较无肝硬化(n = 1112)、代偿期肝硬化(n = 338)和失代偿期肝硬化(n = 251)患者的基线PRO及治疗后PRO变化。

主要发现

  • 失代偿期肝硬化患者基线PRO评分较无肝硬化患者最多低33.5%(P < .05)。
  • 含利巴韦林方案治疗后,代偿期与失代偿期肝硬化患者PRO评分变化相似(所有P > .01)。
  • 含利巴韦林方案使部分PRO评分较基线升高最多11.8%(P < .05),另一些降低最多7.1%(P < .05)。
  • 含利巴韦林方案停药后12周时所有PRO下降均恢复;无论肝硬化状态如何,PRO评分在治疗后最多升高14.2%,治疗后24周最多升高17.1%(肝硬化组间所有P > .01)。
  • 无利巴韦林的索磷布韦联合维帕他韦方案从治疗第4周起提高代偿期肝硬化患者PRO评分,失代偿期肝硬化患者提高更明显,各时间点未观察到统计学显著下降(所有单侧P值 > .05)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The combination of sofosbuvir and velpatasvir is used to treat patients with hepatitis C virus (HCV) infection of different genotypes. We compared the effects of this treatment regimen, with and without ribavirin, on outcomes reported by patients (patient-reported outcomes [PROs]) with HCV infection, with or without cirrhosis. METHODS: We performed a post hoc analysis of data collected from phase 3 clinical trials (ASTRAL-1, -2, -3, and -4) of 1701 patients infected with HCV of different genotypes treated with sofosbuvir and velpatasvir with ribavirin for 12 weeks (n = 87), sofosbuvir with ribavirin for 12 or 24 weeks (n = 401), and ribavirin-free sofosbuvir and velpatasvir for 12 or 24 weeks (n = 1213). In all trials, participants completed 4 PRO questionnaires (while blinded to their HCV RNA levels): the Short Form-36, the Functional Assessment of Chronic Illness Therapy-Fatigue, the Chronic Liver Disease Questionnaire-HCV Version, and the Work Productivity and Activity Impairment: Specific Health Problem, at multiple time points. We compared baseline PROs and changes in PROs following treatment in patients without cirrhosis (n = 1112), with compensated cirrhosis (n = 338), and with decompensated cirrhosis (n = 251). RESULTS: Baseline PRO scores were as much as 33.5% lower in patients with decompensated cirrhosis than in patients without cirrhosis (P < .05). Following treatment with ribavirin-containing regimens, changes in PRO scores were similar among patients with compensated and decompensated cirrhosis (all P > .01). Treatment with these regimens increased some PRO scores by as much as 11.8% from baseline (P < .05) and reduced others, by as much as 7.1% (P < .05). Despite this, by 12 weeks after cessation of treatment with ribavirin-containing regimens, all PRO decrements resolved; PRO scores increased by as much as 14.2%, and as much as 17.1% at 24 weeks after treatment, regardless of cirrhosis status (all P > .01 between cirrhosis groups). In contrast, treatment with ribavirin-free sofosbuvir and velpatasvir increased PRO scores for patients with compensated cirrhosis, and even more so in patients with decompensated cirrhosis starting at treatment Week 4; no statistically significant decrement was observed at any time point (all 1-sided P values > .05). In multivariate analysis, compensated cirrhosis was associated with a 2.3% to 5.0% greater increase in PRO scores following treatment with sofosbuvir and velpatasvir (P < .05); decompensated cirrhosis was associated with a 5.5%-9.1% greater increase (P < .002). Clinicaltrials.gov number, NCT02201940, NCT02220998, NCT02201953, NCT02201901. CONCLUSIONS: In an analysis of data from 4 phase 3 clinical trials, we found that patients with HCV infection (especially those with decompensated cirrhosis) have significant increases in their PRO scores during treatment with sofosbuvir and velpatasvir and after achieving a sustained virologic response.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Younossi ZM, Stepanova M, Feld J, et al. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2016. PMID: 27847279. doi:10.1016/j.cgh.2016.10.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。